Clinical features and prognosis of drug-induced vanishing bile duct syndrome

doi:10.3969/j.issn.1006-7795.2018.05.010

Abstract

Abstract: Objective To analyze the clinical features and outcomes of the drug-induced liver injury (DILI) patients with vanishing bile duct syndrome (VBDS). Methods A total of 1010 patients with DILI were diagnosed clinically from January 2010 to December 2016. Of which, 267 patients underwent liver biopsy, 19 patients were diagnosed DILI with VBDS by histology. At the same time, 54 patients without VBDS were randomly enrolled as a control. The clinical data and outcomes of the two groups of patients were compared. Results In this study, VBDS accounted for 7.12% (19/267). Of DILI patients with VBDS, 73.68% (14/19) patients had cholestasis, 26.32% (5/19) had no jaundice. The majority of VBDS patients were developed to chronic liver injury(88.2% vs 35.2%)compared to those without VBDS. Those drugs included sex hormones drugs(n=2), non-steroidal anti-inflammatory drugs (n=3), immunomodulators drugs (n=3), antibiotics(n=3), herbal products(n=4), hair dye (n=1),proton pump inhibitor (n=1), and antipsychotics(n=1). VBDS patients had significantly higher than those without VBDS serum cholesterol(CHOL)[(8.4±3.9) vs (4.4±1.5)mmol/L], alkaline phosphatase (ALP)[(613.6±544.4)U/L vs (151.8±70.4)U/L], and glutamyl transpeptidase(GGT)[(631.2±472.8)U/L vs (228.7±174.4)U/L] (P<0.05). Conclusion Most DILI patients with VBDS have cholestasis. VBDS may be the pathological basis of patients' development to chronic DILI with poor prognosis.

Key words: drug induced liver injury, vanishing bile duct syndrome, prognosis

CLC Number:

R575

Geng Wenjing, Liu Hui, Fan Chunlei, Li Lei, Dong Peiling, Ding Huiguo. Clinical features and prognosis of drug-induced vanishing bile duct syndrome[J]. Journal of Capital Medical University, 2018, 39(5): 675-679.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.05.010

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I5/675

References

[1] Beger R D, Bhattacharyya S, Yang X, et al. Translational biomarkers of acetaminophen-induced acute liver injury[J]. Arch Toxicol, 2015, 89(9):1497-1522.
[2] Chalasani N, Bonkovsky H L, Fontana R, et al. Features and outcomes of 889 patients with drug-induced liver injury:the DILIN prospective study[J]. Gastroenterology, 2015, 148(7):1340-1352.
[3] Visentin M, Lenggenhager D, Gai Z, et al. Drug-induced bile duct injury[J].Biochim Biophys Acta, 2017, 1864(4 Pt B):1498-1506.
[4] Björnsson E S, Jonasson J G. Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome:rare but has severe consequences[J]. Hepatology, 2017, 65(4):1091-1093.
[5] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 中华肝脏病杂志, 2015, 23(11):810-820.
[6] Ludwig J, Wiesner R H, Batts K P, et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation[J]. Hepatology, 1987, 7(3):476-483.
[7] Ortega-Alonso A, Andrade R J. Chronic liver injury induced by drugs and toxins[J]. J Dig Dis, 2018,Epub ahead of print.
[8] Bénichou C. Criteria of drug-induced liver disorders:report of an international consensus meeting[J]. J Hepatol, 1990, 11(2):272-276.
[9] Bakhit M, Mccarty T R, Park S, et al. Vanishing bile duct syndrome in hodgkin's lymphoma:a case report and literature review[J]. World J Gastroenterol, 2017, 23(2):366-372.
[10] 叶立红, 王翀奎, 张海丛,等. 药物相关性胆管消失综合征的临床病理特征[J].中华肝脏病杂志, 2017, 25(4):317-320.
[11] Bonkovsky H L, Kleiner D E, Gu J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements[J]. Hepatology, 2017, 65(4):1267-1277.
[12] 孙玥, 赵新颜, 贾继东. 药物相关性胆管消失综合征诊断及治疗进展[J]. 肝脏, 2014,19(5):360-362.
[13] Kawasaki Y, Matsubara K, Hashimoto K, et al. Nonsteroidal anti-inflammatory drug-induced vanishing bile duct syndrome treated with plasmapheresis[J]. J Pediatr Gastroenterol Nutr, 2013, 57(5):e30.
[14] Bhayana H, Appasani S, Thapa B R, et al. Lamotrigine-induced vanishing bile duct syndrome in a child[J]. J Pediatr Gastroenterol Nutr, 2012, 55(6):e147-148.
[15] Orman E S, Conjeevaram H S, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury[J]. Clin Gastroenterol Hepatol, 2011, 9(6):517-523.e3.
[16] Geubel A P, Sempoux C L. Drug and toxin-induced bile duct disorders[J]. J Gastroenterol Hepatol, 2000, 15(11):1232-1238.
[17] Capra F, Nicolini N, Morana G, et al. Vanishing bile duct syndrome and inflammatory pseudotumor associated with a case of anabolic steroid abuse[J]. Digest Dis Sci, 2005, 50(8):1535-1537.
[18] Chatterjee S, Annaert P. Drug-induced cholestasis:mechanisms, models, and markers[J]. Curr Drug Metab, 2018, Epub ahead of print.
[19] Paula, Oppenheimer, Christopher, et al. Vanishing bile duct syndrome in human immunodeficiency virus infected adults:A report of two cases[J]. World J Gastroenterol, 2013, 19(1):115-121.
[20] Juricic D, Hrstic I, Radic D, et al. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man[J]. Basic Clin Pharmacol Toxicol, 2010, 106(1):62-65.
[21] Smith L A, Ignacio J R, Winesett M P, et al. Vanishing bile duct syndrome:amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid[J]. J Pediatr Gastroenterol Nutr, 2005, 41(4):469-73.
[22] Jakab S S, West A B, Meighan D M, et al. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome[J]. World J Gastroenterol, 2007, 13(45):6087-6089.